Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma

BACKGROUND: Multiple low-cost biosimilars of bevacizumab are now available but their clinical efficacy has never been compared against the original (innovator) molecule in glioblastoma. The aim of the current analysis is to compare the overall survival (OS) in recurrent/progressive glioblastoma pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ecancermedicalscience
Main Authors: Kumar, Gunjesh, DSouza, Hollis, Menon, Nandini, Srinivas, Sujay, Vallathol, Dilip Harindran, Boppana, Mounika, Rajpurohit, Annu, Mahajan, Abhishek, Janu, Amit, Chatterjee, Abhishek, Krishnatry, Rahul, Gupta, Tejpal, Jalali, Rakesh, Patil, Vijay M
Formato: Artigo
Idioma:Inglês
Publicado em: Cancer Intelligence 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7929766/
https://ncbi.nlm.nih.gov/pubmed/33680080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2021.1166
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados